Original ResearchPreservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
Under a Creative Commons license
open access
Keywords
Metastatic breast cancer
Human epidermal growth factor receptor 2 positive (HER2)
Quality of life
Brain metastases
Tucatinib
Trastuzumab
Cited by (0)
- 1
As of January 2021, Dr. Wardley is employed by AstraZeneca.
© 2021 The Authors. Published by Elsevier Ltd.